Neoadjuvant Therapy Clinical Trial
— nECTOfficial title:
Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Randomized Clinical Phase II Trial
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant electrochemotherapy on locally advanced rectal cancer (UICC II-III) in an intended curative clinical setting, using an endoscopic electroporation device (EndoVE).
Status | Recruiting |
Enrollment | 40 |
Est. completion date | September 2019 |
Est. primary completion date | June 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patient must be mentally capable of understanding the information given. 2. Patients must give written informed consent. 3. Men or women aged at least 18 years. 4. Histologically verified rectal tumor (adenocarcinoma) 5. Case reviewed by MDT (surgery, radiology, oncology). Case considered curable with neoadjuvant therapy followed by surgical excision (UICC stadium II-III). 6. ASA class I-III (Classification of the American Society of Anesthesiology) Exclusion Criteria: 1. Coagulation disorders 2. Highly inflamed gastrointestinal tissue which is ulcerated and bleeding 3. Patients with ICD or pacemaker units. 4. Patients with epilepsy. 5. Pregnancy or lactation/breastfeeding. 6. Patients with known Hepatitis B/C or HIV infection. 7. Patients who have undergone treatment with bevacizumab within 4 weeks prior to enrolment in this trial. 8. Patients with concomitant use of phenytoin. 9. Patients with concomitant use of clozapine. 10. Concurrent treatment with an investigational medicinal product. 11. Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study recruitments. 12. Patients with contraindications for PET/MRI scan: 13. Advanced tumor stage, UICC stage IV. 14. Acute pulmonary infection. 15. Medical history of severe pulmonary disease. 16. Previous allergic reactions to bleomycin. 17. Previous cumulative dose of bleomycin exceeding 250.000 IU/m2. 18. Pre-existing renal dysfunction. Creatinine clearance < 40 ml/min. 19. Platelet count =50 mia/l. 20. Prothrombin time = 40 sec 21. Patients registered in the Danish Tissue Register (Vaevsanvendelsesregistret) |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Oncology | Herlev | Capitol Region |
Denmark | Department of Surgery | Roskilde |
Lead Sponsor | Collaborator |
---|---|
Zealand University Hospital | Herlev Hospital, Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Histopathologic tumor regression following electrochemotherapy | Number of participants with histopathologic tumor regression following elctrochemotherapy as assesed by histopathological evaluation of Tumor Regression Grade (Mandard Classification, TRG 1-5) | 4 weeks | |
Secondary | Treatment safety of electrochemotherapy | Number of participants with treatment-related adverse events as assesed by CTCAE version 4.0 | 4 months | |
Secondary | Treatment safety of surgery following electrochemotherapy | Number of participants with compromized surgery following electrochemotherapy assesed by R1 resection rate, CRM involvement, non-mesorectal resection plane, and post operative complications according to Clavien-Dindo Classification | 4 weeks | |
Secondary | Tumor regression according to Hybrid PET/MRI following electrochemotherapy | Tumor regression as assesed by tumor stage (T-stage) | 4 weeks | |
Secondary | Tumor Immunologic response following electrochemotherapy | Tumor immunologic infiltration as assesed by the Immunoscore through immunohistochemical analysis | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05996484 -
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04520737 -
Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases
|
N/A | |
Recruiting |
NCT06138496 -
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
|
Phase 2 | |
Not yet recruiting |
NCT05983094 -
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
|
Phase 2 | |
Terminated |
NCT04440982 -
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04028375 -
Study of CT and MR in the Gastric Cancer
|
||
Active, not recruiting |
NCT03192735 -
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04588987 -
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
|
Phase 2 | |
Not yet recruiting |
NCT05993858 -
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
|
Phase 2 | |
Active, not recruiting |
NCT04666090 -
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04848454 -
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
|
Phase 2 | |
Recruiting |
NCT04062058 -
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT06124378 -
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06125223 -
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
|
||
Not yet recruiting |
NCT06404736 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404463 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05371197 -
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06212440 -
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
|
N/A | |
Completed |
NCT03178032 -
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
|
Phase 1 |